Pipeline Database
UB356
Search clinical-stage assets by therapeutic area, modality, target, indication, stage and territory — then inquire on any row that fits your brief.
UB356
IndicationsMalignant neoplasm
ClinicalCN - IND
TherapeuticsOncology
ModalitiesNucleic Acid Therapeutics
Exclusive Summary
- **Independent IP & FTO**: Backed by a proprietary mRNA platform with over 270 patent applications, offering partners 'Freedom to Operate' by breaking global patent barriers in LNP and mRNA synthesis.
- **AI-Driven Innovation**: Utilizes AI-assisted protein/mRNA design and proprietary delivery systems (LNP & Non-LNP) to enhance stability and translation efficiency, positioning it as a potential Best-in-Class asset.
- **Validated Platform & CMC**: The underlying technology is validated by CDE approvals for other pipeline assets (RSV/Shingles), supported by in-house GMP pilot plants that ensure cost-effective manufacturing and rapid clinical supply.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →